- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00479037
Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)
A 24-week, International, Multi Centre, Randomised, Open Label, Parallel Group, Phase IV Clinical Trial Investigating Changes in Bone Formation Markers in Postmenopausal Women With Primary Osteoporosis Treated With Either PTH(1-84) or Strontium Ranelate
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Roskilde, Denmark, 4000
- Nycomed
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Postmenopausal women at or above the age of 50, diagnosed with primary osteoporosis may be enrolled in the trial if the following inclusion/exclusion criteria apply.
All inclusion criteria must be answered "yes" for a subject to be enrolled in the trial.
- Has the subject given informed consent according to local requirements before any trial related activities? (A trial related activity is any procedure that would not have been performed during the routine management of the subject).
- Is the subject female and at or above the age of 50?
- Has the subject been postmenopausal for more than 5 years - in the judgement of the investigator?
- Does the subject have primary osteoporosis and a T-score equal to or lower than -2.5 SD; T-scores must be assessed by DXA at the lumbar spine L1-L4, with a minimum of two assessable vertebrae, or at the total hip (right hip, if there is a right hip prosthesis, left hip can be used. If both hips are replaced the subject can be included with a lumbar scan only).
- Is the subject currently taking calcium and vitamin D3 or is she willing to start such supplemental treatment and continue throughout the trial period, unless she develops hypercalcaemia?
- Has the subject been taking supplemental calcium (1,000 mg) and vitamin D3 (800 IU) daily for at least 14 days (after screening) before blood sampling for eligibility evaluation? [*]
- Is the subject able to self-inject PTH(1-84), or get the injections by a helper?
[*] Note that inclusion criteria no. 6 can not be evaluated at the time for screening, must be evaluated at randomisation, visit 2. See also exclusion criteria and note [**].
Exclusion criteria:
All exclusion criteria must be answered "no" for a subject to be enrolled in the trial.
Has the subject:
- been treated with SERMS (selective oestrogen receptor modulators) or calcitonin within the last 1 month?
- ever been treated with any bisphosphonate in intravenous form (i.v.)?
- been treated with any bisphosphonates (alendronate, risedronate, or other bisphosphonates) for more than 3 years in total, or within the last 6 months?
- been treated with fluoride for more than 3 months within the last 10 years?
- ever been treated with strontium ranelate?
- ever been treated with teriparatide or PTH(1-84)?
received or is the subject currently receiving chronic glucocorticosteroid treatment?
Defined as more or equal to:
5.0 mg prednisolon or equivalent daily for 3 months during the last year or 2.5 mg prednisolon or equivalent daily for 6 months during the last year. Local and inhalation steroids are permitted.
- been treated for cancer (other than basocellular skin cancer) within the last 5 years?
- ever received radiation therapy to the skeleton?
- ever had malignant disease affecting the skeleton? or does the subject:
- currently receive antiepileptic medication?
- take any other medication (other than calcium and vitamin D3) that is known to affect bone metabolism? - according to the investigator's opinion.
- have any known clinically significant diseases affecting calcium metabolism?
- have any known history of metabolic bone diseases other than primary osteoporosis including hyperparathyroidism, Paget's disease, osteogenesis imperfecta, or osteomalacia)?
- have any known history of hypersensitivity to parathyroid hormone or strontium or any of the excipients in the products?
- have a serum vitamin D3, (serum 25(OH)D) level <20 ng/ml after at least 14 days of calcium and vitamin D3 supplementation? [**]
- have a serum PTH of > 65 pg/ml and also a total serum calcium value >2.49 mmol/l? [**]
- have hypercalcaemia (total serum calcium value >2.55 mmol/l), measured after at least 14 days of calcium and vitamin D3 supplementation? [**]
- have elevated serum alkaline phosphatase? Defined as > 3X ULN [**]
- have impaired kidney function with creatinine clearance < 30 ml/min (indirect measurement by serum creatinine)? [**]
- have severe impaired liver function ? [**]
- have phenylketonuria? or is the subject:
- at risk of having venous thromboembolism including pulmonary embolism? - according to the investigator's opinion.
- scheduled for vertebroplasty?
- currently participating in a clinical trial with an investigational medical product, or has done so within the last 90 days, or plan to do so within the next 32 weeks? Previous and current participation in non-interventional trials is allowed.
[**] exclusion criteria no. 16 to 21 can not be evaluated before the result of the blood sampling (planned within the screening period and after at least 14 days of supplemental calcium/vitamin D3 intake) is available.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: PTH(1-84)
|
Once daily subcutaneous injection in the abdomen by self administration
Other Names:
|
ACTIVE_COMPARATOR: Strontium Ranelate
|
The daily dose of 2 g (one sachet) strontium ranelate was to be mixed in a glass of water and taken immediately after mixing at bedtime at least 2 hours before or after intake of calcium, any food or drinks, other than water
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Change in the Bone Formation Marker N-terminal Propeptides of Human Procollagen Type I (P1NP) From Baseline to End of Trial
Time Frame: Baseline and 24 weeks of treatment
|
P1NP is a bone formation marker that is derived from the amino-terminal propeptides of type I collagen and is considered a quantitative measure of newly formed type I collagen. Bone marker measurements were done by blood analysis. |
Baseline and 24 weeks of treatment
|
Percentage Change in the Bone Formation Marker Bone Specific Alkaline Phosphatase (BSAP) From Baseline to End of Trial
Time Frame: Baseline and 24 weeks of treatment
|
BSAP is a marker of bone formation that reflects the cellular activity of osteoblasts. Bone marker measurements were done by blood analysis. |
Baseline and 24 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Change in the Bone Resorption Marker C-Telopeptide Cross-links (CTX) From Baseline to End of Trial
Time Frame: Baseline and 24 weeks of treatment
|
CTX is a marker of bone resorption, which is a degradation product of bone collagen. Bone marker measurements were done by blood analysis. |
Baseline and 24 weeks of treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Musculoskeletal Diseases
- Bone Diseases
- Bone Diseases, Metabolic
- Osteoporosis
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Hormones
- Parathyroid Hormone
- Strontium ranelate
Other Study ID Numbers
- FP-006-IM
- 2006-006065-16
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporosis
-
Radius Health, Inc.CompletedOsteoporosis | Osteoporosis Risk | Osteoporosis, Postmenopausal | Osteoporosis Fracture | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae | Osteoporosis VertebralUnited States
-
Radius Health, Inc.CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of VertebraeUnited States, Poland, Italy
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States, Puerto Rico
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruitingPost Menopausal OsteoporosisFrance
-
AmgenCompletedPost Menopausal OsteoporosisFrance
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisSpain, South Africa, Germany, Mexico, United States, Canada, France, United Kingdom, Italy, Belgium, Australia, Poland, Denmark, Hungary, Czech Republic, Norway
-
Hoffmann-La RocheGlaxoSmithKlineCompletedPost Menopausal OsteoporosisFrance
-
Novartis PharmaceuticalsCompletedPost-menopausal OsteoporosisColombia, Belgium, Sweden, Hong Kong, United States, Hungary, Switzerland, Australia, Germany, Italy, Canada, Poland, Argentina, Thailand, Norway, New Zealand, France, Finland
Clinical Trials on Full Length Parathyroid Hormone, PTH(1-84)
-
John P. BilezikianShire; NPS PharmaUnknownHypoparathyroidismUnited States
-
National Institute of Diabetes and Digestive and...Unknown
-
Entera Bio Ltd.Completed
-
University of California, San FranciscoCompleted
-
University of AarhusCompleted
-
University of PittsburghWithdrawnHyperparathyroidism | Osteoporosis | Bone Diseases, Endocrine | Hypercalcemia of MalignancyUnited States
-
ShireCompletedHypoparathyroidismUnited States, Hungary, Canada, Denmark
-
University of PittsburghNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Completed